Objective: The objective of this study was to compare postoperative morphine equivalent (MEQ) intake after open abdominal aortic aneurysm repair among analgesic modalities: standard analgesia (SA) with systemic opioid administration, epidural analgesia (EA), and surgically positioned paravertebral catheter analgesia (PA).
Methods: A retrospective cohort study was performed of all open abdominal aortic aneurysm repairs from 2005 to 2016 at the QEII Health Science Center, Halifax, Nova Scotia. Total MEQ intake (on postoperative day [POD] 1, 2, and 3), time in intensive care, and adverse events were compared between patients with SA, EA, and PA. A multivariable zero inflated Poisson regression was used to determine the association between analgesic modality and MEQ. Multivariable logistic regression models were used to determine associations between analgesic modality and rates of discharge from intensive care within 1 day and adverse events. Adjusting covariates included age, comorbidities, smoking, American Society of Anesthesiologists status, presence of symptoms, anatomic candidacy for endovascular repair, and surgical approach (transperitoneal vs retroperitoneal).
Results: The final study cohort included 355 patients: 177 retroperitoneal and 178 transperitoneal repairs; 117 patients underwent PA, 65 EA, and 173 SA. Compared with SA, PA and EA were associated with decreased MEQ intake on POD 1, 2, and 3 (Table I) . Compared with SA, PA and EA were associated with decreased odds of receiving opioids on POD 1, 2, and 3 (Table II) . If patients did receive opioids, compared with SA, PA and EA were associated with decreased consumption on POD 1 (Table II) . Compared with SA, PA was associated with earlier discharge from intensive care (odds ratio, 2.75; 95% confidence interval, 1.17-6.45). Compared with EA, PA was not associated with increased odds of adverse events (odds ratio, 0.44; 95% confidence interval, 0.08-2.44).
Conclusions: PA and EA are associated with decreased MEQ intake compared with SA. PA is associated with earlier discharge from intensive care compared with SA and similar rates of adverse events compared with EA.
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PAPER SESSION VI: TREATMENT OF VENOUS DISEASE
Results: A total of 18 patients with 19 legs and 22 perforator vein injections were included. The amount of cyanoacrylate injected per perforator was 0.2 mL. The average age of patients was 63 6 3 years, with 61% being female and a body mass index of 25 6 2 kg/m 2 . Clinical, Etiology, Anatomy, and Pathophysiology classification and the location of perforators treated are shown in Table I . Immediate treatment success was noted in all 22 instances. Treatment success was 100% at short-term follow-up. There were three cases of superficial phlebitis noted that had resolved by midterm follow-up. There were no deep venous thromboses or other procedure-related complications noted at midterm follow-up.
Conclusions: Ultrasound-guided direct perforator injection of cyanoacrylate glue is a safe and effective treatment for patients undergoing concurrent superficial vein ablation. Objective: Varicose veins and chronic venous insufficiency are increasingly common diagnoses in the adult population. Valvular incompetency at the saphenofemoral junction is the usual cause of the venous insufficiency, leading to a variety of symptoms. Most traditional endovenous procedures (laser and radiofrequency) require injection of tumescent fluid along the saphenous vein, which can be a cause of significant discomfort for the patient. Newer, nontumescentbased therapies have been introduced with similar success rates and less discomfort, leading to high appeal to patients. The objective of this study was to compare the nontumescent-based endovenous therapies with the standard tumescent-based endovenous therapies in regard to clinical-effectiveness and procedure-related outcomes in patients with saphenofemoral incompetency and varicose veins.
Methods: The following databases were searched for studies that were randomized or quasi-randomized trials comparing nontumescentbased endovenous procedures with those requiring tumescence: Cochrane Central Register of Controlled Trials (1950-January 2017), MED-LINE (1946 -January 2017 , and Embase (1950-January 2017). There were no restrictions based on language or publication status. In the case of ongoing studies, the World Health Organization's International Clinical Trials Registry Platform and the online ClinicalTrials.gov registry were also searched. We also reviewed reference lists of articles relevant to our study to ensure a more complete review. Two authors independently screened and selected studies to include. These two authors also independently assessed the risk of bias using the Cochrane RoB 2.0 tool. Data were extracted and pooled using a random-effects model.
Results: Four outcomes were reviewed. There was a significant difference found between the comparator groups for mean intraprocedural pain score, favoring nontumescent-based therapies. There was no difference for Venous Clinical Severity Score for clinical assessment and the Aberdeen Varicose Vein Questionnaire quality of life score for the disease-specific quality of life between the groups. The outcome of failure of truncal ablation at 30 days had no significant difference between the groups, although a subgroup analysis demonstrated a trend toward improved results with the novel nontumescent-based treatments compared with the old nontumescent-based treatments.
Conclusions: Currently available evidence from reasonable-quality clinical trials comparing tumescent-based with nontumescent-based endovenous therapies shows no overall difference between the groups on a number of outcomes. Mean intraprocedural pain score appears to favor nontumescent-based interventions. Newer randomized trials comparing the treatment modalities are needed to further clarify the benefits of nontumescent-based therapies, particularly with regard to long-term outcomes.
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